Stocks
I
BMY I
Apr 25, 2024, 12:10:42 PM
Bristol Myers Squibb Reports Positive First Quarter 2024 Financial Results
Bristol Myers Squibb (NYSE: BMY) has announced a solid start to 2024 with their first-quarter financial results showing robust revenue growth and strategic advancements. Despite facing significant one-time costs due to acquisitions, the company has made notable progress in expanding its growth portfolio and pipeline.
Financial Performance
- Revenue Growth: Bristol Myers Squibb posted first-quarter revenues of $11.9 billion, marking a 5% increase from the previous year, with a 6% rise when adjusted for foreign exchange impacts. This growth was driven by strong performances in key products such as Eliquis, Reblozyl, and Opdualag, although slightly offset by declines in Opdivo and Revlimid.
- GAAP and Non-GAAP Loss Per Share: The company experienced a GAAP loss per share of $(5.89) and a non-GAAP loss per share of $(4.40), primarily due to one-time acquired IPRD charges from recent strategic acquisitions.
- Strategic Acquisitions: Bristol Myers Squibb strengthened its long-term growth through the completion of significant transactions with Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune.
Operational Highlights
- Regulatory Approvals: The company achieved U.S. approval for Abecma in earlier-line multiple myeloma and Breyanzi in chronic lymphocytic leukemia and small lymphocytic lymphoma. Additionally, positive proof of concept was obtained for Opdualag in non-small cell lung cancer.
- Strategic Productivity Initiative: Bristol Myers Squibb is executing a strategic productivity initiative aimed at delivering approximately $1.5 billion in cost savings, the majority of which will be reinvested to fund innovation and drive growth.
Product Revenue Insights
- Growth Portfolio: The growth portfolio generated revenues of $4.8 billion, an increase of 8% year-over-year, or 11% adjusted for foreign exchange. This segment was significantly boosted by higher demand for Reblozyl, Opdualag, Yervoy, Camzyos, and Sotyktu.
- Legacy Portfolio: The legacy portfolio, including blockbuster drugs like Eliquis and Revlimid, contributed $7.1 billion to the total revenues. While Eliquis saw a 12% increase in sales, Revlimid experienced a slight decline.
Financial Outlook and Strategic Directions
Bristol Myers Squibb is updating its 2024 non-GAAP EPS and line-item guidance to reflect the impact of recently completed transactions. The company remains committed to strengthening its long-term growth profile through continuous innovation, strategic acquisitions, and by maximizing the potential of its diversified product portfolio.